Bioabsorbable exoluminal stent

• US 20030028255A1
• Filed: 03/19/2002
• Published: 02/06/2003
• Est. Priority Date: 05/12/2001
• Status: Abandoned Application

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: Nalwa, Sarvi Singh, Sewall, Gregory K., Connor, Nadine P., Hartig, Gregory K.
• Application Number:
  US10/102,494
• Publication Number:
  US 20030028255A1
• Time in Patent Office: Days
• US Class Current: 623/23.7
• CPC Class Codes: A61F 2/04 Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts A61F2/18, A61F2/20 take precedence; devices, other than stent-grafts, providing patency to, or preventing collapsing of, tubular structures of the body other than stent-grafts, e.g. stents A61F2/82; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95
• CPC Class Codes: A61F 2002/046 Tracheae
• CPC Class Codes: A61F 2210/0004 bioabsorbable

Abstract

Disclosed is an exoluminal stent. The stent includes a bioabsorbable matrix having a plurality of apertures passing therethrough. The matrix is capable of being dimensioned and configured to complement an external diameter of a vessel to be stented. The stent can be adhered to the outer diameter of the vessel to be stented via sutures that pass through the apertures in the matrix.

Claims

1. An exoluminal stent comprising:

a bioabsorbable matrix having a plurality of apertures passing therethrough, wherein the matrix is capable of being dimensioned and configured to complement an external diameter of a vessel to be stented.

2. The exoluminal stent of claim 1, wherein the bioabsorbable matrix comprises poly(lactic acid).

3. The exoluminal stent of claim 1, wherein the bioabsorbable matrix comprises poly(glycolic acid).

4. The exoluminal stent of claim 1, wherein the bioabsorbable matrix comprises a poly(lactic acid)/poly(glycolic acid) copolymer.

5. The exoluminal stent of claim 4, wherein the poly(lactic acid)/poly(glycolic acid) co-polymer comprises from about 50 to about 90 wt % lactic acid monomers and from about 50% to about 10% glycolic acid monomers.

6. The exoluminal stent of claim 4, wherein the poly(lactic acid)/poly(glycolic acid) co-polymer comprises from about 80 to about 90 wt % lactic acid monomers and from about 20% to about 10% glycolic acid monomers

7. The exoluminal stent of claim 1, wherein the bioabsorbable matrix comprises a desaminotyrosyltyrosine ethyl ester.

8. The exoluminal stent of claim 1, wherein the bioabsorbable matrix comprises a homopolymer selected from the group consisting of poly(lactic acid), poly(glycolic acid), poly(caprolactone) and polydioxanone.

9. The exoluminal stent of claim 1, wherein the bioabsorbable matrix comprises a copolymer selected from the group consisting of poly(lactic acid)/(glycolic acid) copolymer, poly(ε

-caprolactone)/(lactide) copolymer, and poly(ε

-caprolactone)/(glycolide) copolymer.

10. An exoluminal stent comprising:

an absorbable matrix comprising a poly(lactic acid)/poly(glycolic acid) co-polymer, the matrix having a plurality of apertures passing therethrough, and wherein the matrix is capable of being dimensioned and configured to complement an external diameter of a vessel to be stented.

11. The exoluminal stent of claim 10, wherein the poly(lactic acid)/poly (glycolic acid) co-polymer comprises from about 50 to about 90 wt % lactic acid monomers and from about 50% to about 10% glycolic acid monomers.

12. The exoluminal stent of claim 10, wherein the poly(lactic acid)/poly(glycolic acid) co-polymer comprises from about 80 to about 90 wt % lactic acid monomers and from about 20% to about 10% glycolic acid monomers

13. A method of externally stenting a vessel in need thereof, the method comprising:

to an external diameter of a vessel to be stented, adhering a bioabsorbable matrix having a plurality of apertures passing therethrough, wherein the matrix is dimensioned and configured to complement the external diameter of the vessel.

14. The method of claim 13, wherein the bioabsorbable matrix comprises poly(lactic acid).

15. The method of claim 13, wherein the bioabsorbable matrix comprises poly(glycolic acid).

16. The method of claim 13, wherein the bioabsorbable matrix comprises a poly(lactic acid)/poly(glycolic acid) copolymer.

17. The method of claim 16, wherein the poly(lactic acid)/poly(glycolic acid) co-polymer comprises from about 50 to about 90 wt % lactic acid monomers and from about 50% to about 10% glycolic acid monomers.

18. The method of claim 16, wherein the poly(lactic acid)/poly(glycolic acid) co-polymer comprises from about 80 to about 90 wt % lactic acid monomers and from about 20% to about 10% glycolic acid monomers

19. The method of claim 13, wherein the bioabsorbable matrix comprises a desaminotyrosyltyrosine ethyl ester.

20. The method of claim 13, wherein the bioabsorbable matrix comprises a homopolymer selected from the group consisting of poly(lactic acid), poly(glycolic acid), poly(caprolactone) and polydioxanone.

21. The method of claim 13, wherein the bioabsorbable matrix comprises a copolymer selected from the group consisting of poly(lactic acid)/(glycolic acid) copolymer, poly(ε

-caprolactone)/(lactide) copolymer, and poly(ε

-caprolactone)/(glycolide) copolymer.

22. The method of claim 13, wherein the vessel to be stented is a trachea.

23. The method of claim 22, wherein the bioabsorbable matrix is adhered to the trachea via sutures passing through the apertures in the matrix.

24. The method of claim 13, wherein the bioabsorbable matrix is adhered to the vessel via sutures passing through the apertures in the matrix.